首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1660072

假性脑瘤市场:现状分析与未来预测 (2024年～2032年)

Pseudotumor Cerebri Market: Current Analysis and Forecast (2024-2032)

出版日期: 2025年01月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

预计预测期内（2024-2032 年），假性脑瘤市场将以 5.5% 的显着复合年增长率成长。假性脑瘤市场的成长主要受到肥胖症成长的推动，肥胖症是导致假性脑瘤的主要原因，尤其是在育龄女性身上。认识的提高和影像和腰椎穿刺解决方案等增强的诊断解决方案是推动假性脑瘤市场发展的因素。该市场的成长得益于对新治疗方法的研究不断增加，包括手术等微创手术和成功的医疗手段。此外，政府加强对抗神经系统疾病，对特发性颅内高压的病理生理学研究，也促进了治疗介入措施的发展，并持续扩大治疗这种疾病的市场潜力。

在假性脑瘤的诊断中，神经影像学领域将在 2023 年占据最高的市场占有率。这种主要表现归功于高科技影像、MRI 和 CT，这些技术很少被发现，但却是排除颅内压升高的其他原因（包括肿瘤和中枢神经系统形态变化）所必需的。神经影像学是诊断的关键组成部分，该技术很常见，并且由于其比其他方法侵入性更小、更准确、更可靠而成为医生的选择。儘管眼底检查领域预计将迅速扩张，但预计近期市场成长将相对保守。这种增长归因于假性脑瘤（特别是视乳头水肿）的早期发现的增加，以及包括 OCT 在内的眼科影像的使用。这些工具提高了诊断的准确性并有助于更早发现疾病，因为早期治疗对于避免视力丧失至关重要。此外，创新且价格合理的检眼镜技术的进步正在推动我们在已开发市场和新兴市场的产品组合。

根据治疗方式，药物治疗在假性脑瘤治疗中占有最高的市场占有率。一线药物为乙酰唑胺、托吡酯。这些是最常用的，因为它们可以减少脑脊髓液的形成和实际颅内压。与其他治疗方法相比，它是一种非侵入性、成本更低、更容易患者和医生接受的治疗方法，尤其是在病情严重程度为轻度至中度时。然而，预计未来几年静脉窦支架领域将具有巨大的成长潜力。这是由于治疗与静脉窦狭窄（最常见的原因）相关的假性脑瘤的疗效正在显现。静脉窦支架置入术是一种微创方法，在控制颅内压和改善症状方面已被证明具有有效的效果，其长期效果可直接针对病理生理原因。

基于最终用户，医院部门在假性脑瘤的诊断和治疗中占有最高的市场占有率。该医院是一家第一线医疗机构，拥有方便使用的神经影像设施、包括腰椎穿刺在内的诊断设备，以及执行分流术和静脉窦支架术等外科手术的能力。此外，拥有神经科医生、眼科医生和外科医生等各类专科医生的医院治疗严重疾病，因此该领域的需求很高。然而，由于多种因素，包括神经和眼科疾病专门治疗门诊的机会改善，预计未来诊所部门将会扩大。

为了更了解假性脑瘤的市场介绍，我们根据其在北美（美国、加拿大和欧洲其他地区）、欧洲（德国、法国、英国、西班牙、义大利和欧洲其他地区）、亚太地区（中国、日本、印度和亚太地区其他地区）和世界其他地区的全球市场表现进行分析。由于肥胖率上升、医疗成本不断上涨、疾病意识增强以及医疗旅游重要性日益增加等因素，预计亚太地区未来将经历最高的成长。医疗保健的扩张以及中国、印度和日本等亚太地区国家的尚未开发的市场使亚太地区成为一个关键的成长市场。

市场的主要参与者包括McKesson Corporation，参天製药株式会社，Sanofi，Polpharma，Pfizer Inc.，Sandoz AG，Viatris Inc.，Medtronic Plc.，SOPHYSA，Teva Pharmaceutical Industries Ltd.，Medtronic Plc.等。

Pseudotumor cerebri, also known as idiopathic intracranial hypertension (IIH), is a neurological disorder in which the pressure that surrounds the brain and spinal cord (intracranial pressure) is higher than normal, but there is no inflammation, infection, tumor, or other conditions that can explain this increase. This condition is more prevalent in pregnant women and women of childbearing age with excess body weight or obesity. The exact etiology has yet to be ascertained although it is likely related to a malfunction in the regulation of CSF. The early symptoms are usually chronic headaches, and changes in vision, for example, blurring, diplopia or temporary loss of vision, pulsating tinnitus, and increased intracranial pressure papilledema. If left untreated may lead to permanent blindness. Diagnostics consists of clinical examination and assessment, brain imaging to rule in and out other pathological possibilities, and obtaining CSF pressure by lumbar puncture. Management involves a reduction of intracranial pressure, for which some patients may be recommended to lose weight, take medications, particularly acetazolamide, undertake optic nerve sheath fenestration, or spinal fluid shunt should be used if the condition becomes extreme.

The Pseudotumor Cerebri Market is expected to grow with a significant CAGR of 5.5% during the forecast period (2024-2032). The pseudotumor cerebri market is majorly driven by increased incidences of obesity, which is a major cause of pseudotumor cerebri especially among women of childbearing age. Rising awareness and enhancing diagnostic solutions like imaging solutions and lumbar puncture solutions are the factors that drive the pseudotumor cerebri market. The growth of the market is due to the increasing research of new treatment methods, which may include minimal invasions, such as surgical operations and successful medication therapeutics. Furthermore, increased efforts by the governments to combat neurological disorders, and research on the pathophysiology of idiopathic intracranial hypertension contribute to the development of therapeutic interventions, which continue to extend the market potential for the management of this disorder.

In the diagnosis of pseudotumor cerebri, the neuroimaging segment has the highest market share in the year 2023. This dominance is due to high-tech imaging, MRI, and CT, which are required to rule out other causes of raised ICP, including tumors or altered CNS morphology, although rarely identified. Neuroimaging is an important component in diagnostics and this technique is common due to its lack of invasiveness, accuracy, and reliability as compared to other methods making it doctors' choice. While the growth of the market in the near future is relatively conservative, the fundoscopy segment is likely to show rapid expansion. This growth is attributable to the rising incidence of early recognition of pseudotumor cerebri, particularly papilledema, and the use of ophthalmic imaging, including OCT. These tools improve diagnostic precision and aid in early detection of the ailment as early treatment is critical to avoid vision loss. Also, advances in innovative and affordable fundoscopy technology have enriched product offerings in both developed and emerging markets.

Based on treatment, the medication segment has the highest market share in the treatment of pseudotumor cerebri. The first-choice drugs are acetazolamide and topiramate; they are most commonly used because they help reduce CSF formation and actual intracranial pressure. It is non-invasive, cheaper, and more easily accessible to the patient and physician than other forms of treatment, especially in cases of mild to moderate severity of the illness. However, the segment covering venous sinus stenting is expected to have great potential for growth in the future. This was attributed to the rising confirmation of the therapeutic effects in the management of pseudotumor cerebri related to venous sinus stenosis, the most prevalent cause. The approach of venous sinus stenting is less invasive and provides a long-term outcome directly targeting the pathophysiologic cause with evidenced effective outcomes in controlling the intracranial pressure and symptomatic improvement.

Based on the end-user, the hospital segment accounts for the highest market share in the diagnosis as well as in the treatment of Pseudotumor Cerebri. Hospitals are the first-line healthcare facilities with easy ability to access diagnostic equipment including neuroimaging facilities and lumbar puncture and to carry out surgical processes such as shunting or venous sinus stenting. Also, severe types of diseases are treated in hospitals with various specialists such as neurologists, ophthalmologists, and even surgeons leading to huge demand for this segment. However, the clinics segment is anticipated to expand in the future due to numerous factors such as enhanced access to outpatient clinics specialized in treating neurological and ophthalmological conditions.

For a better understanding of the market adoption of Pseudotumor Cerebri is analyzed based on its worldwide presence in regions such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific region will have the highest future growth due to factors such as rising obesity rates, escalating healthcare expenditure, improving disease awareness, and the growing importance of medical tourism. Healthcare expansion and the largely untapped markets in APAC countries such as China, India, and Japan make APAC an important growth market.

Some of the major players operating in the market include McKesson Corporation, Santen Pharmaceutical Co., Ltd., Sanofi, Polpharma, Pfizer Inc., Sandoz AG, Viatris Inc., Medtronic Plc., SOPHYSA, Teva Pharmaceutical Industries Ltd.

1.MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Pseudotumor Cerebri Market
2.2. Research Methodology of the Pseudotumor Cerebri Market
2.3. Respondent Profile

3.EXECUTIVE SUMMARY

3.1. Industry Synopsis
3.2. Segmental Outlook
- 3.2.1. Market Growth Intensity
3.3. Regional Outlook

4.MARKET DYNAMICS

4.1. Drivers
4.2. Opportunity
4.3. Restraints
4.4. Trends
4.5. PESTEL Analysis
4.6. Demand Side Analysis
4.7. Supply Side Analysis
- 4.7.1. Merger & Acquisition
- 4.7.2. Investment Scenario
- 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

5.1. Regional Pricing Analysis
5.2. Price Influencing Factors

6.GLOBAL PSEUDOTUMOR CEREBRI MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY DIAGNOSIS

7.1. Fundoscopy
7.2. Neuroimaging
7.3. Lumbar Puncture
7.4. Others

8.MARKET INSIGHTS BY TREATMENT

8.1. Spinal Fluid Shunt
8.2. Optic Nerve Sheath Fenestration
8.3. Venous Sinus Stenting
8.4. Medication

9.MARKET INSIGHTS BY END-USER

9.1. Hospitals
9.2. Clinics
9.3. Others

10.MARKET INSIGHTS BY REGION

10.1. North America
- 10.1.1. U.S.
- 10.1.2. Canada
- 10.1.3. Rest of North America
10.2. Europe
- 10.2.1. Germany
- 10.2.2. U.K.
- 10.2.3. France
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
10.3. Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Rest of Asia-Pacific
10.4. Rest of World

11.VALUE CHAIN ANALYSIS

11.1. Marginal Analysis
11.2. List of Market Participants

12.COMPETITIVE LANDSCAPE

12.1. Competition Dashboard
12.2. Competitor Market Positioning Analysis
12.3. Porter Five Forces Analysis

13.COMPANY PROFILES

13.1. McKesson Corporation
- 13.1.1. Company Overview
- 13.1.2. Key Financials
- 13.1.3. SWOT Analysis
- 13.1.4. Product Portfolio
- 13.1.5. Recent Developments
13.2. Santen Pharmaceutical Co., Ltd
13.3. Sanofi
13.4. Polpharma
13.5. Pfizer Inc.
13.6. Sandoz AG
13.7. Viatris Inc.
13.8. Medtronic plc
13.9. SOPHYSA
13.10. Teva Pharmaceutical Industries Ltd.

14.ACRONYMS & ASSUMPTION

15.ANNEXURE

02-2729-4219

+886-2-2729-4219

License/价格

假性脑瘤市场:现状分析与未来预测 (2024年～2032年)

Pseudotumor Cerebri Market: Current Analysis and Forecast (2024-2032)

目录

第1章市场概要

第2章分析方法或前提条件

第3章摘要整理

第4章市场动态

第5章价格分析

第6章全球假性脑瘤的市场收益 (2022～2032年)

第7章市场分析:诊断

第8章市场分析:各治疗法

第9章市场分析:各终端用户

第10章市场分析:各地区

第11章价值链分析

第12章竞争情形

第13章企业简介

第14章缩写与前提条件

第15章附录